[Expert consensus on diagnosis and treatment of renal cell cancer bone metastasis (2021 edition)].

Bone is a common metastatic site of renal cell carcinoma (RCC), with about 30% of metastatic RCC patients are suffering from bone metastasis. More than 70% of RCC patients with bone metastasis may experience skeletal related events (SREs), which may severely impair patients' quality of life and even shorten their survival time. Therefore, SREs prevention has become one of the treatment objectives of RCC bone metastasis. Bone-modifying agents are the basic treatment of bone metastases in addition to anti-tumor therapy. The treatment of RCC bone metastasis also requires multi-disciplinary team and individualized comprehensive treatment strategies. To standardize the diagnosis and treatment of RCC bone metastasis in China, the expert group of Genitourinary Oncology Committee, Chinese Anti-cancer Association has formulated the expert consensus for the reference of clinical practice, to improve the general therapeutic level of RCC with bone metastasis and benefit more patients.骨转移是肾癌的常见转移部位，约30%的转移性肾癌合并骨转移，超过70%的肾癌骨转移患者会出现骨相关事件(SREs)，SREs严重影响患者的生活质量，甚至可能缩短患者的生存时间。因此，预防SREs的发生是肾癌骨转移治疗的主要目标之一。除基础抗肿瘤治疗之外，骨改良药物也是肾癌骨转移的基础治疗。肾癌骨转移的治疗需采用多学科综合治疗模式，制定个体化的综合诊疗方案。中国抗癌协会泌尿男生殖系统肿瘤专业委员会专家组形成共识以规范中国肾癌骨转移的诊疗模式，以提高肾癌骨转移的整体治疗水平，惠及更多患者。.